0001193125-26-076596
SEC filingRevenue declined 15% due to diagnostics asset sales, while operating loss improved 23% on cost reductions and gains.
OPKO Health describes itself as a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. The company operates through two reportable segments: pharmaceuticals and diagnostics. The pharmaceuticals segment includes commercial products NGENLA (a once-weekly human growth hormone injection partnered with Pfizer) and Rayaldee (for secondary hyperparathyroidism in CKD), as well as a robust early-stage pipeline from its ModeX subsidiary (multispecific antibodies and vaccines). The diagnostics segment consists of BioReference Health, a specialized laboratory that was strategically realigned after divesting non-core assets to Labcorp for up to $462.5 million in 2024 and 2025.
The pharmaceuticals segment covers operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and global R&D. The diagnostics segment is primarily BioReference's clinical laboratory operations, now focused on core clinical testing in New York/New Jersey and the national 4Kscore test franchise. There are no significant inter-segment sales, and segment performance is evaluated based on operating profit or loss.
Commercial products: NGENLA (somatrogon-ghla) for pediatric growth hormone deficiency, Rayaldee (extended-release calcifediol) for SHPT in stage 3/4 CKD, and the 4Kscore prostate cancer test. Pipeline highlights from ModeX include MDX2001 (tetraspecific antibody, Phase 1), MDX2003 (tetraspecific for hematological tumors, preclinical), MDX2004 (trispecific immune modulator, first patient dosed Oct 2025), and an EBV nanoparticle vaccine (Phase 1 with Merck). Also, peptide programs: OPK-88006 (oxyntomodulin) for obesity/MASH, oral formulations via Entera collaboration, and oral GLP-2 for Short Bowel Syndrome.
Rayaldee is marketed directly in the U.S. and through partners VFMCRP (Europe, Japan) and Nicoya (Greater China). NGENLA is commercialized globally by Pfizer, and OPKO receives a tiered gross profit share. BioReference has a U.S.-based sales team and relies on in-network contracts with large health plans. The 4Kscore test benefits from a Category I CPT code and positive Medicare coverage. No single customer concentration is disclosed.
In pharmaceuticals, Rayaldee competes with vitamin D analogs and supplements from larger companies. NGENLA faces long-acting growth hormones from Ascendis Pharma and Novo Nordisk, as well as generic daily hGH. In diagnostics, BioReference competes with national laboratories in its core New York/New Jersey markets, and the 4Kscore test competes with other prostate cancer diagnostics.
OPKO's growth strategy rests on five pillars: (1) advancing the ModeX multispecific pipeline, (2) expanding the portfolio through collaborations and license agreements, (3) maximizing NGENLA's global value via Pfizer and additional indications like SGA, (4) executing Rayaldee's international expansion (China, Europe, Japan), and (5) optimizing specialty diagnostics by scaling the 4Kscore test following its 2025 FDA label expansion.
As of December 31, 2025, OPKO had 2,275 full-time employees worldwide, with only an immaterial number in Spain covered by a collective bargaining agreement. The company emphasizes health and safety, competitive benefits, and talent development, including a dedicated Head of Learning and Training.
For the year ended December 31, 2025, total revenue decreased 15% to $606.9 million from $713.1 million in 2024. The decline was primarily driven by a 23% decrease in services revenue to $370.3 million, reflecting the sale of BioReference's lab and oncology operations. Product revenue remained relatively flat at $156.9 million (up 1%), and intellectual property revenue increased 3% to $79.7 million. Gross margin improved to 33.9% from 30.6% in the prior year, benefiting from a shift in revenue mix and lower cost of revenue in the diagnostics segment. Operating loss improved 23% to $117.4 million, driven by a $101.6 million gain on the Oncology Transaction and a $93.7 million reduction in cost of revenue.
Diagnostics segment revenue fell 23% to $370.3 million, largely due to the divestiture of BioReference assets. However, the segment swung to an operating income of $21.3 million from a loss of $24.1 million, aided by a $101.6 million gain on asset sales and a 37% reduction in SG&A expenses. Core clinical test volume in continuing operations declined, but higher reimbursement rates (+$9.4 million) and 13% growth in 4Kscore revenue provided partial offsets.
Pharmaceuticals segment revenue grew 2% to $236.6 million, supported by a $4.8 million increase from the BARDA contract, $4.3 million in Eli Lilly royalties from Mazdutide, and a $7.2 million upfront from Regeneron. These gains were partially offset by the absence of a $12.5 million Merck milestone. Segment operating loss worsened to $98.3 million from $86.8 million, as R&D spending rose 18% to $121.9 million, primarily on higher manufacturing expenses and ModeX headcount.
Corporate segment operating loss improved slightly to $40.3 million from $41.1 million, reflecting lower employee-related expenses.
Management stated that cash, cash equivalents and restricted cash of $382.7 million as of December 31, 2025 are sufficient to meet anticipated needs beyond 12 months. Key upcoming milestones include a late 2026 IND filing for the oral LA-PTH program with Entera and initial Phase 1 data for injectable OXM in late 2026. The BARDA contract was de-scoped by $6.5 million to $103.5 million, with $49.9 million in remaining performance obligations as of year-end. The company also has a $200 million share repurchase program authorized, with $50.6 million in shares repurchased through December 31, 2025. Future performance depends on achievement of regulatory and commercial milestones from partnered programs and sustained cost discipline.
As of December 31, 2025, OPKO held $369.1M in cash and equivalents (plus $14.2M in investments) against total debt of $344.0M, resulting in a net cash position of approximately $39.3M. Shareholders' equity stood at $1,268M, down from $1,365M a year earlier, primarily due to the net loss of $225.7M and share repurchases. The debt composition shifted: the 2044 Senior Secured Notes ($246.4M) remained stable, while the 2029 Convertible Notes were reduced to $85.0M from $173.6M following the April 2025 exchange transactions. Cash used in operations was $178.5M for the year.
The Notes did not disclose material purchase commitments or contractual obligations beyond debt and lease liabilities. The company is contingently liable for an Israeli tax assessment of approximately $246M (including interest), which is being appealed.
The company operates in two reportable segments: Pharmaceutical and Diagnostics. However, the Notes did not provide detailed segment revenue or operating income; instead, revenues are classified by type (services, products, IP/other). Approximately 28% of revenue was denominated in non-USD currencies, primarily Chilean Peso and Euro. No fine-grained segment economics were disclosed in the Notes section.
OPKO Health continues to face significant financial uncertainty, with a history of operating losses outside the COVID-19 testing surge in 2020-2021. The company's pharmaceutical business generates limited revenue, and profitability hinges on successful commercialization of Rayaldee and NGENLA. The $679.3 million in goodwill and intangible assets, particularly in the diagnostics segment ($163.4M) and Ireland reporting unit ($89.5M), are at risk of impairment if performance targets are not met. The company's reliance on Pfizer for NGENLA is a critical vulnerability—Pfizer can terminate the agreement with 90 days' notice, which would eliminate milestone and profit-share revenue.
PAMA-driven Medicare rate cuts for clinical laboratory tests are scheduled to resume in 2027, with annual reductions capped at 15% through 2029. This poses a direct threat to the diagnostics segment's revenue. The company also faces extensive regulatory oversight from the FDA, CLIA, and international bodies; failure to maintain compliance could result in operational shutdowns or significant penalties. The ongoing Corporate Integrity Agreement with OIG-HHS adds compliance burdens and potential monetary penalties.
Concentrated insider ownership (49.61% of voting securities, with Dr. Frost holding 33.15%) and a significant short position (11.7% of outstanding shares) create stock price volatility. The company's ability to raise capital may be constrained by market conditions and debt covenants under the $250 million senior secured notes issued in 2024.
Cybersecurity threats, including AI-enhanced attacks, pose risks to patient data and operational continuity. The company's reliance on third-party manufacturers and clinical investigators introduces supply chain and trial execution risks. International operations in Israel, Mexico, and Europe expose the company to geopolitical instability, currency fluctuations, and FCPA compliance challenges.
No cash flow statement data was provided in the input excerpt. The document contains auditor reports and revenue recognition discussions but lacks the actual cash flow figures. Therefore, no analysis can be performed.